ITGAV

Across TCGA pan-cancer cohorts, ITGAV Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated ITGAV data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ITGAV Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ITGAV expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

OV, UCEC, and DLBC are the cancer types where ITGAV Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.028	0.844	<.001	48	view →
UCEC	DFS	Median	All	0.941	0.621	.008	32	view →
DLBC	OS	Median	All	0.049	0.765	<.001	30	view →
HNSC	OS	Median	II,III,IV	0.058	0.712	<.001	30	view →
BLCA	DFS	Median	IV	0.129	0.483	.002	12	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
LUSC	DFS	Median	All	1.000	0.363	.020	4	view →
LGG	OS	Median	All	0.291	0.799	.004	3	view →
ESCA	OS	Median	II,III,IV	0.321	0.685	.035	3	view →
SKCM	OS	Median	II,III,IV	0.451	0.746	.005	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

ITGAV–OV (OS)

Open the OV breakdown →